Gina Hurst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gina Hurst has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Emanuel P. Rivers
Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI 48202, USA
2 shared publications Jacqueline Pflaum-Carlson
Henry Ford Hospital
2 shared publications- Jacqueline Pflaum-Carlson
J. Pflaum-Carlson is a combined emergency, internal, and critical care medicine physician and program director of the combined program, Henry Ford Hospital, Detroit, Michigan; telephone: (313) 916-1553;
2 shared publications Jayna Gardner-Gray
Henry Ford Hospital
2 shared publications- Jayna Gardner-Gray
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Henry Ford Hospital, Detroit, USA
2 shared publications - Namita Jayaprakash
Department of Emergency Medicine, Henry Ford Hospital, Henry Ford Health, Detroit
2 shared publications
Latest Publications
- 18 November 2021
- Published by Springer Nature
- p. 1-10
Overview of the COVID-19 Infection
- Open Access
- 25 September 2020
- Published by Western Journal of Emergency Medicine in Western Journal of Emergency Medicine
- Vol. 21 (6) , 107-109
Responding to a Pandemic: The Role of EM-CCM on ICU Boarders in an Urban Emergency Department
Author(s): Pflaum-Carlson, Jacqueline; Gardner-Gray, Jayna; Jayaprakash, Namita; Hurst, Gina; Coba, Victor; Kinni, Harish; Rivers, Emanuel
- 25 September 2020
- Published by Western Journal of Emergency Medicine in Western Journal of Emergency Medicine
- Vol. 21 (6) , 107-109
Open AccessResponding to a Pandemic: The Role of EM-CCM on ICU Boarders in an Urban Emergency Department
Author(s): Pflaum-Carlson, Jacqueline; Gardner-Gray, Jayna; Jayaprakash, Namita; Hurst, Gina; Coba, Victor; Kinni, Harish; Rivers, Emanuel
- Open Access
- 1 July 2016
- Published by Springer Nature in Critical Care
- Vol. 20 (1) , 1-16
Early goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE
Prior to 2001 there was no standard for early management of severe sepsis and septic shock in the emergency department. In the presence of standard or usual care, the prevailing mortality was over 40-50 %. In response, a systems-based approach, similar to that in acute myocardial infarction, stroke and trauma, called early goal-directed therapy was compared to standard care and this clinical trial resulted in a significant mortality reduction. Since the publication of that trial, similar outcome benefits have been reported in over 70 observational and randomized controlled studies comprising over 70,000 patients. As a result, early goal-directed therapy was largely incorporated into the first 6 hours of sepsis management (resuscitation bundle) adopted by the Surviving Sepsis Campaign and disseminated internationally as the standard of care for early sepsis management. Recently a trio of trials (ProCESS, ARISE, and ProMISe), while reporting an all-time low sepsis mortality, question the continued need for all of the elements of early goal-directed therapy or the need for protocolized care for patients with severe and septic shock. A review of the early hemodynamic pathogenesis, historical development, and definition of early goal-directed therapy, comparing trial conduction methodology and the changing landscape of sepsis mortality, are essential for an appropriate interpretation of these trials and their conclusions.
- 1 July 2016
- Published by Springer Nature in Critical Care
- Vol. 20 (1) , 1-16
Open AccessEarly goal-directed therapy in severe sepsis and septic shock: insights and comparisons to ProCESS, ProMISe, and ARISE
Prior to 2001 there was no standard for early management of severe sepsis and septic shock in the emergency department. In the presence of standard or usual care, the prevailing mortality was over 40-50 %. In response, a systems-based approach, similar to that in acute myocardial infarction, stroke and trauma, called early goal-directed therapy was compared to standard care and this clinical trial resulted in a significant mortality reduction. Since the publication of that trial, similar outcome benefits have been reported in over 70 observational and randomized controlled studies comprising over 70,000 patients. As a result, early goal-directed therapy was largely incorporated into the first 6 hours of sepsis management (resuscitation bundle) adopted by the Surviving Sepsis Campaign and disseminated internationally as the standard of care for early sepsis management. Recently a trio of trials (ProCESS, ARISE, and ProMISe), while reporting an all-time low sepsis mortality, question the continued need for all of the elements of early goal-directed therapy or the need for protocolized care for patients with severe and septic shock. A review of the early hemodynamic pathogenesis, historical development, and definition of early goal-directed therapy, comparing trial conduction methodology and the changing landscape of sepsis mortality, are essential for an appropriate interpretation of these trials and their conclusions.
- Open Access
- 10 November 2015
- Published by Springer Nature in Journal of Intensive Care
- Vol. 3 (1) , 1-5
Vancomycin-induced acute generalized exanthematous pustulosis (AGEP) masquerading septic shock—an unusual presentation of a rare disease
Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous adverse reaction characterized by acute sterile pustular eruptions, mostly induced by medications. Antibiotics are the most commonly implicated drugs; however, there have only been two previous reports of vancomycin-induced AGEP in the literature. In this case, we present the clinical course of a 56-year-old man who was admitted to the intensive care unit with an unusually severe form of AGEP mimicking septic shock, which developed after the recent use of vancomycin. Despite cessation of the offending agent, our patient continued to clinically decline with development of worsening skin eruptions and hemodynamic instability necessitating vasopressor support. The patient promptly responded to systemic steroid therapy with complete resolution of AGEP. In addition to highlighting the implication of vancomycin in AGEP, we herein discuss the clinical presentation, diagnosis, and management of AGEP, particularly in severe cases admitted to the intensive care unit.
- 10 November 2015
- Published by Springer Nature in Journal of Intensive Care
- Vol. 3 (1) , 1-5
Open AccessVancomycin-induced acute generalized exanthematous pustulosis (AGEP) masquerading septic shock—an unusual presentation of a rare disease
Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous adverse reaction characterized by acute sterile pustular eruptions, mostly induced by medications. Antibiotics are the most commonly implicated drugs; however, there have only been two previous reports of vancomycin-induced AGEP in the literature. In this case, we present the clinical course of a 56-year-old man who was admitted to the intensive care unit with an unusually severe form of AGEP mimicking septic shock, which developed after the recent use of vancomycin. Despite cessation of the offending agent, our patient continued to clinically decline with development of worsening skin eruptions and hemodynamic instability necessitating vasopressor support. The patient promptly responded to systemic steroid therapy with complete resolution of AGEP. In addition to highlighting the implication of vancomycin in AGEP, we herein discuss the clinical presentation, diagnosis, and management of AGEP, particularly in severe cases admitted to the intensive care unit.